Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IgPro20 in Secondary Immune Deficiency Due to Hematologic Malignancies
NCT07648264Phase 3Recruiting
- Sponsor
- CSL Limited
- Start
- Sep 2026
- Primary completion
- Sep 2029
- Countries
- 11
01
Overview
A Phase 3 trial of IgPro20 in secondary immune deficiency (SID), sponsored by CSL Limited. Started Sep 2026; status: recruiting.
02
Drugs
IgPro20
03
Conditions
secondary immune deficiency (SID)
Beyond the preview
Go deeper on NCT07648264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07648264.